Brief: Inhalerx Receives A$38.5M Funding To Fully Fund Clinical Development Plans
18/10/2024 01:49
Oct 18 (Reuters) - Inhalerx Ltd IRX.AX :
* A$38.5M FUNDING TO FULLY FUND CLINICAL DEVELOPMENT PLANS
Further company coverage: IRX.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nexalis Therapeutics
See all newsBrief: Nexalis Therapeutics Says Sean Williams Has Resigned As Non-Executive Chairman
Brief: Nexalis Therapeutics Signs Funding Partnership With Point8 Capital To Replace Existing Facility
Brief: Nexalis Therapeutics Seeks Trading Halt
Brief: Nexalis Therapeutics Says US Policy Market Advancement Supports SRX-25 TRD Treatment
Australia's Nexalis Therapeutics gains most in over 6 months on trial approval